Atezolizumab + Bevacizumab
Treatment for Liver Cancer Due To Nash
Typical Dosage: Atezolizumab 1200mg IV every 3 weeks + Bevacizumab 15mg/kg IV every 3 weeks
Effectiveness
88%
Safety Score
35%
Clinical Trials
10
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Atezolizumab 1200mg IV every 3 weeks + Bevacizumab 15mg/kg IV every 3 weeks
Time to Effect
1-2 months
Treatment Duration
until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300,000
Monitoring:$8,000
Side Effect Mgmt:$15,000
Total Annual:$323,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$1,196,296
Cost per Remission
$5,383,333
Comparison vs Sorafenib
Cost Difference
+$250,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Atezolizumab + Bevacizumab Outcomes
for Liver Cancer Due To Nash
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+27%
Remission Rate
+6%
Common Side Effects
Hypertension (grade 3-4)
+23%
Fatigue
+42%
Diarrhea
+24%
Proteinuria (grade 3-4)
+8%
Hemorrhage/Bleeding (grade 3-4)
+15%
Immune-related hepatitis
+10%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov